The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib-Reference-Cited by-同舟云学术

The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib

Published:2023-08 Issue: Volume:248 Page:108475
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Di Vito Aldo,Ravegnini Gloria,Gorini Francesca,Aasen Trond,Serrano César,Benuzzi Eva,Coschina Emma,Monesmith Sarah,Morroni Fabiana,Angelini Sabrina,Hrelia Patrizia

Funder

Instituto de Salud Carlos III

European Regional Development Fund

European Commission

Ministero dell’Istruzione, dell’Università e della Ricerca

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference65 articles.

1. Non-coding RNAs, a novel paradigm for the management of gastrointestinal stromal tumors;Amirnasr;International Journal of Molecular Sciences,2020

2. The emerging role of the FGF/FGFR pathway in gastrointestinal stromal tumor;Astolfi;International Journal of Molecular Sciences,2020

3. GIST tumors: Who should get imatinib and for how long?;Balachandran;Advances in Surgery,2014

4. Ripretinib versus Sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with Imatinib (INTRIGUE): A randomized, open-label, phase III trial;Bauer;Journal of Clinical Oncology,2022

5. Prospective multicentric randomized phase III study of Imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French sarcoma group;Blay;Journal of Clinical Oncology,2007

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Arbutus unedo L. Fractions Exhibit Chemotherapeutic Properties for the Treatment of Gastrointestinal Stromal Tumors;Plants;2024-04-25

2. Efficient cocrystal coformer screening based on a Machine learning Strategy: A case study for the preparation of imatinib cocrystal with enhanced physicochemical properties;European Journal of Pharmaceutics and Biopharmaceutics;2024-03

3. KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST;Cell Communication and Signaling;2024-02-27

4. Design, synthesis and anticancer evaluation of imamine-1,3,5-triazine derivatives;New Journal of Chemistry;2024